The move to the new building is being done in two phases: the support functions (marketing, sales, finance, etc.) moved into the new building in July and the laboratory employees will move in this fall.
The new building will allow us to continue to cater to the exponential growth in demand for raw materials for ATMP development and manufacturing. Indeed, we will be able to meet the expectations of the gene and cell therapy market as it moves from late-stage clinical development to commercialization, as well as the continued increase in R&D and pre-clinical development of gene therapy.
This is a great achievement for Polyplus-transfection, as we are celebrating 20 years of innovation in transfection this year!
The completion of Vectura will allow us to double our staff in its manufacturing and development department of transfection reagents for gene and cell therapy, do not hesitate to consult our open positions!